Organisation paid for research Program year 2025 Source: CMS Open Payments

NRC Research Institute

Neither a doctor nor a teaching hospital

Research payments

$2,133,231

559 payments

Through program year 2025, NRC Research Institute is reported as receiving $2,133,231 in research payments, across 559 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $581,327 218
2024 Research $672,427 11
2023 Research $68,912 10
2022 Research $44,319 11
2021 Research $82,506 60
2020 Research $297,356 191
2019 Research $386,385 58

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $568,917 266 payments
  2. Sage Therapeutics, Inc. $436,133 1 payment
  3. Supernus Pharmaceuticals, Inc. $354,103 51 payments
  4. ACADIA Pharmaceuticals Inc $321,447 29 payments
  5. BioXcel Therapeutics, Inc. $163,837 9 payments
  6. Alkermes, Inc. $83,749 37 payments
  7. Avanir Pharmaceuticals, Inc. $54,579 13 payments
  8. E.R. Squibb & Sons, L.L.C. $48,175 3 payments
  9. H. Lundbeck A S $33,037 5 payments
  10. Genentech, Inc. $26,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $436,133 1 payment
  2. A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD $246,821 83 payments
  3. Acp-103-059 $206,159 12 payments
  4. Phase II DRF study of NR2B modulation in MDD $178,972 2 payments
  5. Bxcl501401 $163,837 9 payments
  6. Acp-103-055 $98,597 15 payments
  7. A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia $97,074 116 payments
  8. Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) $95,894 15 payments
  9. A Phase IV, Open-Label, Flexible-Dose Safety Trial Evaluating Spn-812 Administered With Psychostimulants in Children and Adolescents (6 to 17 Years of Age) With Disorder (Adhd) Attention-Deficit/Hyperactivity $63,931 9 payments
  10. Open-Label Extension Study to Evaluate the Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder $47,100 7 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $23,702 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record